Biosimilars market booming with a huge CAGR of 49.1% by 2020.| Top key players are Novartis (Sandoz), Synthon Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/700?utm_source=openpr&utm_medium=Niranjan
Europe would continue to dominate the market while the Asia Pacific would emerge as the fastest growing region over the forecast period.
The recent approval of Zarxio (filgrastim-sndz) as the first biosimilar by U.S. FDA has opened new opportunities for biosimilar manufacturers. Patents for the number of blockbuster bio-pharmaceuticals have either expired or are on the verge of expiration, which is majorly driving the growth of biosimilars industry. Changes in regulatory guidelines and convenient biosimilar drug approval processes have a major impact on the commercial growth of the global biosimilars market.
However, the high investment associated with research and development, longer development processes and requirements of economies of scale for profitability largely limit the growth of biosimilars market. The integration of developmental plan with regulatory guidelines and the adoption of optimal commercial strategies would play a crucial role in the commercial growth of the biosimilars market.
Glycosylated proteins namely, erythropoietin and monoclonal antibodies are the leading biosimilar segments commercially available across the globe, together accounting for about one-third of the market revenue in 2014. This significant hold in the market is chiefly due to its large application in the treatment of chronic conditions such as blood-related disorders, cancer, among others.
Purchase Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/700?utm_source=openpr&utm_medium=Niranjan
Key findings of the Global Biosimilars Market:
- The biosimilar applications in blood disorders and oncology collectively evaluated at 61% in 2014.
- Interferon is the fastest growing biosimilar, expected to grow at a CAGR of 51.1% during the forecast period.
- The U.S. would find space in the biosimilar market with a single-digit revenue share of overall biosimilar market by 2020.
The European region is the leading beneficiary of the biosimilars market and is attracting investors, interested in the biosimilars industry. The prospects in the European region are largely supplemented by the presence of streamlined regulatory guidelines and a high level of adoption for biosimilars among physicians. The establishment of favorable regulations such as Article 10(4) of Directive 2001/83/EC by the European Medical Association (EMA) has clarified the clinical aspect of biosimilars.
This standard set by EMA has attracted investors to invest in the development of biosimilars. The Asia-Pacific region projects the fastest growth rate, supplemented by the high prevalence of chronic diseases and the growing demand for economic bio-pharmaceuticals. The commercial scenario of biosimilars in North America is bleak due to the absence of regulations for approval and commercialization. However, after the launch of the first biosimilar in the United States, the investors are now focusing on this region to boost their prospects.
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars market booming with a huge CAGR of 49.1% by 2020.| Top key players are Novartis (Sandoz), Synthon Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd here
News-ID: 1709757 • Views: 237
More Releases from Allied Market Research
Electric Passenger Car Traction Motor Market Growth 2027 – Key drivers, Busine …
Traction motor produces resistance between two surfaces with or without using electricity. An electric passenger car traction motor is a vital component which is used for extracting electricity from the battery pack. Traction motor is installed in electric passenger vehicles to provide rotation torque for the movement of the car. Furthermore, stringent emission discharge norms and regulations drives the demand for electric passenger car. Moreover, quick expansion of EV charging
Electric Passenger Car Lithium-Ion Battery Management System Market Analysis of …
Electric passenger car has gained a considerable consumer popularity & acceptance in the past few years. Major improvements in the performance of an electric passenger car such as high acceleration rate and long driving range after a single charge have been boosting the demand for electric passenger vehicle. Further, a lithium-ion battery (LIB) is a type of rechargeable battery, which is popularly used in the field of electric passenger vehicles
Electric Bus Door System Market Trending Technologies, Developments, Key Players …
Buses have had a strong place in the transportation industry since the 1830s when the first steam bus was introduced in London. Since the year 1830, buses are considered as the most common mode of public transportation in almost every country across the world. Electric bus door system is an assembly of interconnected mechanisms which utilizes the power of electricity to automatically open the door. Furthermore, the electric bus
Commercial Vehicle & Off-Highway RADAR Market Trends, Segments, Emerging Technol …
Commercial & off-highway vehicles are large and utilized for multiple tasks such as transport of goods, mining, excavation, and others. Due to their large sizes and complicated applications, these vehicles are prone to accidents. Safety concerns increase with a high number of blind spots, thereby propelling the use of RADARs in these vehicles to alert the driver of various threats. In addition, safety & security has become a topmost priority
More Releases for Biosimilars
PHASE-XS – Access To Life Changing Biosimilars
Biopharmaceutical is one of the fastest growing industries with addition of numerous biologics that provide novel treatment modalities for life-threatening and rare diseases. Biologics are produced from living organisms through unique manufacturing and purification processes. It includes a wide variety of products such as vaccines, blood, blood components, cells, allergens, genes, tissues, and recombinant proteins that are derived from human, animal or microorganisms by using biotechnological procedures. Some examples for
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Humira Biosimilars Clinical Trial Insight
“Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. The patent protection assigned to Humira will expire in 2016 for US and 2018 for European market.
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on